Clinical Trial Update: Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 clinical trial evaluated high-dose Coenzyme Q10 for effects on oxidative damage biomarkers and clinical outcomes in Parkinson disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Coenzyme Q10 (Coenzyme Q10)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Parkinson Disease | Phase 2, Phase 3 | Status: COMPLETED